Accelerate your preclinical oncology research and target discovery pipelines with our specialized Organoid Whole Exome Sequencing (WES) services. Engineered specifically to handle the complexities of micro-input samples, we deliver comprehensive, end-to-end multi-omics solutions. From stringent nucleic acid extraction to highly customized tumor-normal concordance analysis, our expert team ensures the genomic fidelity of your 3D models, transforming delicate biological materials into actionable, publication-ready data.
Optimized for Micro-Input: Reliably sequence organoid samples previously deemed too small for standard platforms.
Stringent Multi-Node Quality Control: Transparent checkpoints safeguarding data integrity at every step.
Custom Concordance Bioinformatics: Deep mutational profiling to validate the genetic consistency between your models and primary tissues.
Overcoming the Micro-Input Challenge in Organoid WES
One of the most significant bottlenecks in translational organoid research is securing a sufficient quantity of high-quality DNA for sequencing. Primary tissue-derived organoids, particularly those established from fine-needle aspiration (FNA) biopsies or rare tumor subtypes, often yield extremely limited biomass. Traditional sequencing providers typically rely on standardized bulk tissue protocols, which frequently result in library preparation failures, severe amplification bias, or compromised read depth when applied to micro-input organoid samples.
Our specialized Organoid WES service is designed specifically to solve this challenge. By leveraging highly optimized nucleic acid extraction protocols and low-input library preparation strategies, we can successfully capture the entire exome from exceptionally small starting materials. We carefully minimize the need for excessive PCR amplification cycles, thereby reducing artificial bias and preserving the true somatic mutation landscape of your models.
Whether you are cultivating delicate organoids in-house or receiving models from a collaborative biobank, our specialized workflow ensures that your precious samples are handled with the utmost precision. We empower Research and Development Directors and Principal Investigators to proceed with confidence, knowing that their limited samples will yield the robust genomic data necessary for downstream drug screening and biomarker validation.
A standard list of mutations is rarely sufficient for complex translational research. Our computational biology team provides a highly structured, deep analytical pipeline designed to extract maximum value from your micro-input samples. Every Organoid WES project includes the following comprehensive standard analysis workflow:
Raw Data Processing: Rigorous data cleaning, including the removal of adapter sequences, contamination, and low-quality reads.
Reference Sequence Alignment Analysis: Comprehensive mapping accompanied by detailed sequencing depth and sequencing coverage statistics.
Variant Detection:
Non-tumor models: High-confidence SNV and INDEL detection.
Tumor models (Paired tumor/normal analysis): Somatic SNV, INDEL, and CNV detection for the tumor model; SNV and INDEL detection for the matched normal tissue.
ANNOVAR Annotation: Detailed mapping and contextualization of identified variants.
Gene Structure Annotation: Identifying the genomic localization and structural context of mutations.
Known Variant Database Annotation: Cross-referencing alterations with established genomic databases.
Pathogenicity Prediction: Assessing the functional impact and potential severity of identified mutations.
Functional Database Annotation: Mapping genomic findings to relevant biological pathways.
Mutational Spectrum Concordance Analysis: Deep profiling to validate the genetic consistency and drift between the 3D models and their corresponding primary tissues.
For research programs investigating heterogeneity at an even higher resolution, the genomic profiles obtained here can be seamlessly integrated with our single-cell RNA sequencing (scRNA-seq) services for a comprehensive multi-omics perspective.
To ensure that your in vitro models accurately represent the original tissue pathology, proving genetic consistency is non-negotiable. Our bioinformatics team delivers visually compelling, publication-ready analytics that directly address this need, specifically focusing on the genetic relationship between the model and its origin.
Tumor-Normal Concordance Mapping: Evaluating the genetic consistency between the cultured organoid and the primary tissue is critical. We provide detailed mutational concordance scatter plots and heatmaps that map allele frequencies and mutational overlaps. This allows your research team to visually and quantitatively confirm that the organoid accurately recapitulates the original tumor's genomic landscape.
Mutational Concordance Scatter Plot
Key Applications
Key Applications of Organoid WES in Translational Research
By establishing the genomic baseline and fidelity of your 3D models, our WES services unlock a wide array of high-value applications across the preclinical and translational research spectrum.
Drug Target Discovery & Validation
Identifying novel somatic mutations and structural variations within a stable, tissue-derived context allows researchers to validate new therapeutic targets with a higher degree of confidence than traditional 2D cell lines afford.
Drug Sensitivity Correlation
By linking comprehensive genomic profiles to in vitro organoid drug responses, research teams can robustly identify predictive biomarkers for translational stratification.
Tumor Evolution & Clonal Dynamics
Serial WES analysis of organoids over multiple passages enables researchers to track subclonal dynamics, monitoring how the tumor's genetic architecture evolves under the selective pressure of culture conditions.
Preclinical Biomarker Identification
Our deep sequencing depth allows for the reliable detection of low-frequency variants, aiding in the preclinical screening and validation of predictive biomarkers before committing to expensive in vivo studies.
Workflow & QC
End-to-End Workflow with Stringent QC Checkpoints
We understand that processing precious organoid samples requires zero margin for error. Our workflow is designed with rigorous, transparent quality control checkpoints at every critical transition, ensuring that you receive reliable data or are alerted to sample limitations before incurring unnecessary sequencing costs.
Sample Receipt & Initial Assessment: Upon arrival, samples are carefully logged, and the preservation buffer is inspected.
Micro-Input Nucleic Acid Extraction: We utilize specialized reagents to extract genomic DNA from minimal biomass. QC Checkpoint: DNA integrity and concentration are assessed using highly sensitive fluorometric assays to ensure suitability for library construction.
Advanced Library Construction & Target Enrichment: We employ optimized low-input library prep kits, followed by precise exome capture probes to enrich coding regions while minimizing off-target sequencing. QC Checkpoint: Library fragment size distribution and molarity are rigorously evaluated before pooling.
High-Throughput Sequencing: Libraries are sequenced on state-of-the-art Illumina high-throughput platforms, ensuring deep, uniform coverage across the targeted exome. QC Checkpoint: Initial raw data (FastQ) quality is checked for Q30 scores, GC content, and adapter contamination.
Custom Bioinformatics & Data Delivery: Raw data is processed through our customized pipelines, culminating in the secure delivery of your comprehensive, interactive reports and raw sequencing files.
Profiling Strategy
Choosing the Right Profiling Strategy: Custom Organoid WES vs. Standard Bulk WES
Selecting the correct sequencing strategy is crucial for budget optimization and scientific accuracy. While standard bulk tissue WES is appropriate for large-scale studies, it often falls short when dealing with the unique demands of organoid modeling.
Feature / Dimension
Custom Organoid WES (Our Service)
Standard Bulk WES (Generic CROs)
Micro-input Handling
Highly optimized for <1g or needle biopsy yields
Often requires high DNA mass; prone to failure
Concordance Analysis
Deep focus on Tumor-Normal genetic consistency
Basic variant lists; lacks concordance mapping
Customization Depth
Tailored pathway analysis and signature profiling
Rigid, automated, one-size-fits-all pipelines
Data Application
Model validation, precision drug screening
General routine screening, broad profiling
Solution Selection Strategy:
Opt for Custom Organoid WES when your primary goal is verifying the genomic fidelity of precious, low-yield tissue-derived models. This is the optimal path when every sample is critical and deep validation of the model's relevance is required.
Choose standard Bulk WES for large-scale, routine tissue screening where sample volume is abundant and advanced tumor-normal modeling is not the primary objective.
Case Study: Leveraging Organoids for Precision Liver Cancer Research
Liver cancer presents a significant global health challenge with high molecular heterogeneity. Traditional models often fail to capture this diversity. Researchers aimed to develop primary liver cancer (PLC) organoids to serve as accurate platforms for drug testing and precision research.
The research team successfully established organoids from primary liver cancer tissues. To validate these models, they utilized comprehensive genomic profiling, including Whole Exome Sequencing, to compare the mutational landscape of the newly established organoids against their matched parent tumor tissues.
The bioinformatics analysis revealed a striking preservation of genetic architecture. As highlighted in Figure 1 of the publication, the concordance analysis demonstrated that the somatic mutational profiles, including critical driver gene mutations and copy number variations, were highly consistent between the organoids and the original primary tissues.
The WES profiling provided the definitive genomic evidence required to prove that PLC-derived organoids successfully recapitulate the genetic features of primary liver cancer. This confirmed the validity of the models, establishing them as robust, highly relevant tools for precision translational screening.
To ensure the highest quality nucleic acid extraction and library preparation, please adhere to the following sample submission parameters. If your samples fall outside these general guidelines, please contact our project managers for a customized handling protocol.
Sample Type
Recommended Input
Container
Shipping Conditions
Fresh Organoid Tissue
0.6g (approx. 3 soybeans) or ≥3-needle biopsy
Tissue preservation buffer
2-8°C with ice packs Avoid freeze-thaw cycles.
Matched Normal Tissue
>0.5g (if available for paired analysis)
Tissue preservation buffer
2-8°C with ice packs Essential for accurate variant filtering.
Q1. How do you handle extremely low-input organoid samples (e.g., from needle biopsies)?
We utilize specialized nucleic acid extraction kits formulated specifically for micro-biomass recovery. Furthermore, our library construction workflow incorporates low-input adapter ligation and highly efficient amplification strategies that maximize library complexity while minimizing GC bias, ensuring successful sequencing even from FNA-derived models.
Q2. Can I customize the bioinformatics pipeline for specific pathway analyses?
Absolutely. We recognize that every research objective is unique. Beyond standard variant calling, our bioinformatics team can customize the pipeline to focus on specific gene panels, signaling pathways, or utilize specific functional annotation databases relevant to your research area.
Q3. How is the genetic concordance between the organoid and primary tissue calculated?
Concordance is assessed by comparing the frequency and presence of somatic single nucleotide variants (SNVs), insertions/deletions (INDELs), and copy number variations (CNVs) between the paired samples. We calculate the overlap percentage of shared mutations and generate correlation plots of variant allele frequencies (VAF) to quantitatively demonstrate the degree of genomic similarity.
Disclaimer: All services and products detailed on this page are intended for Research Use Only (RUO). They are not intended for use in diagnostic procedures, clinical decision-making, or any therapeutic applications.
For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.
Inquiry
x
Quote Request
CD Genomics is transforming biomedical potential into precision insights through seamless sequencing and advanced bioinformatics.
